Division of Rheumatology, University of Colorado School of Medicine, 1775 Aurora Court, Mail Stop B-115, Aurora, CO 80045, USA.
Curr Rheumatol Rep. 2012 Oct;14(5):472-80. doi: 10.1007/s11926-012-0275-1.
Data now suggest that current strategies in the treatment of rheumatoid arthritis (RA) should focus on early identification and diagnosis, followed by early initiation of DMARD therapy. Initiation of treatment in early RA-ideally, less than 3-6 months after symptom onset-improves the success of achieving disease remission and reduces joint damage and disability. While the optimal treatment regimen in early RA is unclear, use of initial DMARD mono- or combination therapy with prompt escalation to achieve low disease activity or remission is an appropriate approach. Ultimately, the goal of RA management should be the prevention of inflammatory joint disease and, thereby, prevention of disability. To date, studies have shown that pharmacologic interventions can delay progression from undifferentiated inflammatory arthritis to classifiable RA. However, further investigation is needed to identify asymptomatic individuals at high risk for future RA and to intervene early enough in the pathogenesis of RA to prevent progression to clinical disease.
目前的数据表明,类风湿关节炎(RA)的治疗策略应侧重于早期识别和诊断,然后尽早开始 DMARD 治疗。在早期 RA 中开始治疗(理想情况下,症状出现后 3-6 个月内)可提高实现疾病缓解的成功率,并减少关节损伤和残疾。虽然早期 RA 的最佳治疗方案尚不清楚,但初始 DMARD 单药或联合治疗并迅速升级以实现低疾病活动度或缓解是一种合适的方法。最终,RA 管理的目标应该是预防炎症性关节疾病,从而预防残疾。迄今为止,研究表明,药物干预可以延缓未分化炎症性关节炎向可分类 RA 的进展。然而,需要进一步研究以确定未来患 RA 风险高的无症状个体,并在 RA 的发病机制中尽早干预,以防止疾病进展至临床疾病。